2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179094
    PSP-0119
    PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 (IC50 = 2.83 nM). PSP-0119 can inhibit IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML).
    PSP-0119
  • HY-179100
    Tyrosinase-IN-45
    Tyrosinase-IN-45 is a tyrosinase inhibitor (IC50 = 1.51 μM). Tyrosinase-IN-45 can reduce the melanin content. Tyrosinase-IN-45 can be used for skin whitening and improving pigmentation.
    Tyrosinase-IN-45
  • HY-179112
    PROTAC IKKβ/NR4A1 degrader-1 2826215-20-5
    PROTAC IKKβ/NR4A1 degrader-1 is a highly efficient and effective dual-PROTAC degrader targeting IKKβ and NR4A1. PROTAC IKKβ/NR4A1 degrader-1 can increase the levels of caspase 3 and cleaved caspase 3 proteins, while the necroptosis marker RIP kinase remained unchanged, indicating that it can induce apoptosis. PROTAC IKKβ/NR4A1 degrader-1 can be used for the study of Acute myeloid leukemia (AML). Red: IKKβ/NR4A1 ligand (HY-13067); Blue: E3 ligase CRBN ligand (HY-14658); Black: Linker (HY-79577).
    PROTAC IKKβ/NR4A1 degrader-1
  • HY-179113
    IL-17A-IN-5
    IL-17A-IN-5 (Compound 9) is an orally active IL-17A inhibitor. IL-17A-IN-5 demonstrates a clear dose-dependent inhibition of arthritis.
    IL-17A-IN-5
  • HY-179115
    CHI3L1 binder 1 1381229-36-2
    CHI3L1 binder 1 (Compound A9) is a CHI3L1 binder with a Kd of 182 µM. CHI3L1 binder 1 can be used in the research of immunity, tissue remodeling, and cancer.
    CHI3L1 binder 1
  • HY-179126
    BChE/MAO-A-IN-1
    BChE/MAO-A-IN-1 is a BChE/MAO-A inhibitor. BChE/MAO-A-IN-1 exhibits inhibitory activity against BChE (IC50 = 0.03 nM) and MAO-A (IC50 = 0.32 nM), while also having inhibitory effects on MAO-B. BChE/MAO-A-IN-1 has good anti glycation, antioxidant activity, and low cytotoxicity. BChE/MAO-A-IN-1 can be used in the research of diabetes and Alzheimer's disease.
    BChE/MAO-A-IN-1
  • HY-179131
    TN-783 2771021-30-6
    TN-783 is an orally active, brain-penetrant NLRP3 (IC50 = 19.3 nM) inhibitor. TN-783 enhances the effects of the GLP-1 receptor agonist semaglutide. TN-783 requires sustained targeted action, not permanent metabolic remodeling. TN-783 can be used for the study of obesity.
    TN-783
  • HY-179132
    TN-101 2771020-68-7
    TN-101 is an orally active NLRP3 inhibitor (IC50 = 29.8 nM). TN-101 can be used for the study of obesity.
    TN-101
  • HY-179142
    COX-2-IN-60 3073624-74-2
    COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy.
    COX-2-IN-60
  • HY-179147
    cGAS-IN-6 98%
    cGAS-IN-6 is a cGAS inhibitor. cGAS-IN-6’s core structure is a fused imidazole ring system. cGAS-IN-6 can be used for research on autoimmune conditions.
    cGAS-IN-6
  • HY-179155
    PI3K/mTOR-IN-19
    PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer.
    PI3K/mTOR-IN-19
  • HY-179166
    PROTAC sEH-degrader-4
    PROTAC sEH-degrader-4 is a highly efficient PROTAC degrader that targets soluble epoxide hydrolase (sEH) (pDC50 = 10.3). PROTAC sEH-degrader-4 can be used for research on inflammation-related diseases. Pink: sEH ligand (HY-179169); Blue: E3 ligase CRBN ligand (HY-179168); Black: Linker.
    PROTAC sEH-degrader-4
  • HY-179168
    Thalidomide-C4-N2-C2-N3 2825005-43-2
    Thalidomide-C4-N2-C2-N3 is an E3 ligase ligand. Thalidomide-C4-N2-C2-N3 can bind to a target protein ligand with a linker to form a PROTAC molecule, PROTAC sEH-degrader-4 (HY-179166).
    Thalidomide-C4-N2-C2-N3
  • HY-179169
    sEH-H ligand 2
    sEH-H ligand 2 is an sEH inhibitor and a ligand for the target protein for PROTAC (sEH). sEH-H ligand 2 can be used to synthesize PROTAC sEH-degrader-4 (HY-179166).
    sEH-H ligand 2
  • HY-179209
    TLR9-IN-2 2972638-16-5
    TLR9-IN-2 (Compound 20) is a selective inhibitor of Toll-like receptor 9 (TLR9) with IC50 values for TLR9, TLR7, and TLR8 of 25, 1400, and > 50,000 nM respectively. TLR9-IN-2 can be used for the study of fibrosis, autoimmune and inflammatory diseases.
    TLR9-IN-2
  • HY-179222
    Deoxy-thalidomide-OMe 1061605-49-9
    Deoxy-thalidomide-OMe is an E3 ligase ligand. Deoxy-thalidomide-OMe can be used for synthesis of PROTAC LRRK2 Degrader-4 (HY-178796).
    Deoxy-thalidomide-OMe
  • HY-179226
    AP-7-168 2816062-15-2
    AP-7-168, molecular glues, is a β-arrestin-biased negative allosteric modulator of the β2-adrenergic receptor (β2AR). AP-7-168 can promote β2AR homodimerization and inhibit GRK5-mediated β2AR phosphorylation. AP-7-168 can sustain bronchorelaxation in cell and tissue. AP-7-168 can be used for the researches of inflammation and immunology, such as asthma.
    AP-7-168
  • HY-179246
    CXT29
    CXT29 is an orally active COX-2 inhibitor and a thromboxane A2 receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC50 values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC50 of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases.
    CXT29
  • HY-179274
    β2AR agonist 5 2759727-47-2
    β2AR agonist 5 (Compound alpha-β2-008) is a β2AR agonist, with an EC50 value of 0.19 nM. β2AR agonist 5 induces the BRET signal. β2AR agonist 5 can be used in the research of asthma and chronic obstructive pulmonary disease.
    β2AR agonist 5
  • HY-179292
    USP1-IN-14 3084277-96-0
    USP1-IN-14 (compound 27) is a ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of 0.001 µM. USP1-IN-14 can be used for USP1-related cancers, autoimmune and inflammatory disorders research.
    USP1-IN-14
Cat. No. Product Name / Synonyms Application Reactivity